The clearest win is triglycerides. Prescription-grade omega-3 at 4 grams a day drops fasting triglycerides 20 to 30 percent in a couple of months, one of the most reliable lab moves in nutrition 1. In the exact population it was tested on (high triglycerides, already on a statin) it cut serious heart events, one prevented for every 21 people treated 2.
For everyone else, it depends on your plate. The largest healthy-adult trial found no overall heart benefit. But among people eating under 1.5 fish servings a week, it cut heart attacks by 40 percent 3. Supplementing works when it's correcting a gap. If you already eat fish, you're topping off a full tank.
Depression is the third case. As an add-on to an antidepressant that hasn't fully worked, EPA-heavy fish oil is a defensible extra, when EPA is most of the dose 4 5. Not a replacement for treatment.
First, work out which of the three you are. The dose follows the reason, not a generic fish-oil number.
The timeline is a blood test, not a feeling.
- Weeks: fasting triglycerides start dropping, showing on a lab panel within 4 to 12 weeks.
- Three months: your red-blood-cell omega-3 level reaches a new steady state 6. Mood add-ons usually register by now.
- Years: for the low-fish-eater, a gentler slope on heart risk. You won't feel it; it shows up as an event that didn't happen.
The fine print — when to skip it, and what people get wrong
"More is better, it's just a vitamin." At 4 grams a day, trials picked up more new atrial fibrillation, around a quarter higher 7. "Flax counts." Its ALA converts to EPA at 5 to 10 percent, DHA under 1 percent; no substitute for fish or algae oil.
Check first if you have atrial fibrillation, its risk factors, or a strong family history; the high-dose AF signal tilts against you 7. On warfarin, DOACs, or dual antiplatelets, high-dose EPA extends bleeding time, so tell your prescriber.
- 1Skulas-Ray AC, Wilson PWF, Harris WS, et al. (2019). Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation. link
- 2Bhatt DL, Steg PG, Miller M, et al. (2019). Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). New England Journal of Medicine. link
- 3Manson JE, Cook NR, Lee IM, et al. (2019). Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer (VITAL). New England Journal of Medicine. link
- 4Sublette ME, Ellis SP, Geant AL, Mann JJ (2011). Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. Journal of Clinical Psychiatry. link
- 5Mocking RJT, Harmsen I, Assies J, et al. (2016). Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Translational Psychiatry. link
- 6Harris WS, Von Schacky C (2004). The Omega-3 Index: a new risk factor for death from coronary heart disease? Preventive Medicine. link
- 7Gencer B, Djousse L, Al-Ramady OT, et al. (2021). Effect of Long-Term Marine omega-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Circulation. link
დაკავშირებული სახელმძღვანელოში (9)
- — One of omega-3's narrower real uses is dry eye from meibomian gland dysfunction.
- — EPA-heavy fish oil is a defensible add-on when depression is stuck on a drug — alongside, not instead of, exercise.
- — At high doses the same fish oil that lowers triglycerides raises atrial-fibrillation risk — more is not better.
- — For low-grade inflammation and sore joints, omega-3 and turmeric pull the same lever; omega-3 is the safer pick if you take prescription drugs.
- — A high triglyceride reading on this panel is exactly the result that makes omega-3 worth taking — outside that, it mostly isn't.
- — Omega-3 is one of the residual-risk add-ons after statins — specifically for high triglycerides, not LDL itself.
- — Omega-3 and NAD precursors often share a shelf, but omega-3 has settled indications while NAD's clinical payoff is unproven.
- — The other half of the fat-ratio question is whether adding omega-3 on top helps the way cutting seed oils does.
- — An adjacent topic in the handbook.
Omega-3 (EPA and DHA)
OTC store-brand fish oil at 1-2 g/day EPA+DHA runs $20-50/year. Prescription icosapent ethyl is $3,000+/year absent insurance but reserved for specific cardiovascular/triglyceride indications.
One or two softgels with a meal once daily. Trivial behavioural lift; the only friction is remembering.
Multiple large RCTs (REDUCE-IT n=8,179; VITAL n=25,871; STRENGTH n=13,078; OMEMI n=1,014), Cochrane meta-analysis of 86 trials and 162,796 participants (Abdelhamid 2020), dose-response meta-regression (Bernasconi 2021), and AHA Science Advisory (Skulas-Ray 2019). Results are mixed by population and dose — strong for hypertriglyceridaemia, modest for primary prevention, conditional for mood, weak for cognition — but the trial base is substantial.
Triglyceride reduction is reliable at prescription dose (20-30% in moderate hypertriglyceridaemia, >30% in severe) within 4-12 weeks (Skulas-Ray 2019). Inflammatory markers (CRP, IL-6) drop modestly at 1-3 g/day across meta-analyses. Felt experience is minimal; the short-term benefit is biochemical, visible on labs.
Cochrane 2020 (86 trials, n=162,796) found a small CHD mortality reduction (RR 0.93) and CHD events reduction (RR 0.91) but little effect on all-cause mortality (Abdelhamid 2020). REDUCE-IT showed substantial MACE reduction in statin-treated hypertriglyceridaemic patients (HR 0.75, NNT 21), but STRENGTH was null at the same dose (Bhatt 2019, Nicholls 2020). VITAL primary CV composite was null; total MI reduction was concentrated in low-fish-intake subgroup (Manson 2019). Effect is conditional on baseline status (fish-deficient, elevated TG).
Meta-analyses converge on a modest antidepressant effect in MDD when EPA constitutes ≥60% of EPA+DHA (Sublette 2011: SMD 0.56; Mocking 2016: SMD 0.39 as antidepressant augmentation). Effect-size scales with EPA dose; signal largest when used as adjunct to existing antidepressants and in patients with elevated baseline inflammation. Not a first-line monotherapy; legitimate adjunct.